Drug
Multi-kinase Inhbitor AIV001 clinical trials
Also written AIV001.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
- AIV001
- 4
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
AiViva BioPharma, Inc. (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses Multi-kinase Inhbitor AIV001 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma SubtypeCompletedPhase 1/2AiViva BioPharma, Inc.NCT04470726Written as AIV001
- Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following KeloidectomyCompletedPhase 1AiViva BioPharma, Inc.NCT04827875Written as AIV001
- A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical IncisionCompletedPhase 1/2AiViva BioPharma, Inc.NCT03639883Written as AIV001
- A Safety and Efficacy Study to Evaluate RosaceaWithdrawnPhase 1/2AiViva BioPharma, Inc.NCT03883945Written as AIV001